Scholarlink

<p>Cancer stem cells (CSCs) are a small subpopulation bearing self-renewal ability, mediating tumor initiation and propagation. Several molecular pathways, including the PI3K/AKT/mTOR pathway, are known to be aberrantly activated in cancers. In CSCs, PI3K/AKT/mTOR pathway has been associated with attribution of various properties to cancer cells including stemness characteristics, proliferation, migration, epithelial to mesenchymal transition, and autophagy. Thus, targeting PI3K/AKT/mTOR pathway with novel inhibitors might help to control the growth and proliferation of the breast CSC population. Though many studies have focused on PI3K/AKT/mTOR pathway in breast cancer, limited literature is available on the role of PI3K/AKT/mTOR pathway in breast CSCs. Here, in our present review, we have highlighted the role of the PI3K/AKT/mTOR signaling pathway in breast CSCs and its applications in therapeutic targeting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月17日

查看全文
  • Kirti S. Prabhu,
  • Shilpa Kuttikrishnan,
  • Zahwa Mariyam,
  • Ummu Habeeba,
  • Anu Jayanthi Panicker,
  • Tariq Masoodi,
  • Kulsoom Junejo,
  • Shahab Uddin

摘要

Cancer stem cells (CSCs) are a small subpopulation bearing self-renewal ability, mediating tumor initiation and propagation. Several molecular pathways, including the PI3K/AKT/mTOR pathway, are known to be aberrantly activated in cancers. In CSCs, PI3K/AKT/mTOR pathway has been associated with attribution of various properties to cancer cells including stemness characteristics, proliferation, migration, epithelial to mesenchymal transition, and autophagy. Thus, targeting PI3K/AKT/mTOR pathway with novel inhibitors might help to control the growth and proliferation of the breast CSC population. Though many studies have focused on PI3K/AKT/mTOR pathway in breast cancer, limited literature is available on the role of PI3K/AKT/mTOR pathway in breast CSCs. Here, in our present review, we have highlighted the role of the PI3K/AKT/mTOR signaling pathway in breast CSCs and its applications in therapeutic targeting.